Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma. Issue 11 (8th April 2021)

• Record Type: Journal Article
• Authors: Watanabe, Kageaki; Okuma, Yusuke; Kawai, Shoko; Nagamata, Makoto; Hosomi, Yukio
• Is Part Of: Thoracic cancer. Volume 12:Issue 11(2021)
• Page Start: 1668
• Page End: 1672
• Publication Date: 2021-04-08
• Subjects: amrubicin -- anthracyclines -- case series -- malignant pleural mesothelioma; Chest -- Cancer -- Periodicals; Chest -- Cancer -- Treatment -- Periodicals; Chest -- Surgery -- Periodicals; 616.99494005
• DOI: 10.1111/1759-7714.13892
• Languages: English
• ISSNs: 1759-7706

Abstract

Abstract: Background: Treatment options for malignant pleural mesothelioma (MPM) are limited. Anthracyclines are considered key drugs for treating MPM. However, their use is limited by severe cardiac toxicities. Amrubicin (AMR) is a next‐generation anthracycline that is commonly used to treat lung cancer. Here, we conducted a phase II trial of this drug in patients with previously treated MPM. Methods: Eligible patients with MPM having adequate organ function and a performance status of 0–2 were enrolled after disease progression following pemetrexed/platinum therapy. Patients received 35 mg/m 2 AMR on days 1–3 every three weeks until tumor progression or the appearance of unacceptable toxicities. The primary endpoint was the objective response rate. Median progression‐free survival (PFS), overall survival (OS), number of treatment cycles, and adverse events were evaluated as secondary endpoints. Results: This trial was discontinued because of low accrual. From September 2013 to July 2018, five patients with MPM were enrolled. Stable disease (SD) was observed in three patients (60%), and progressive disease was noted in two patients (40%). The median PFS was 2.4 (range, 1.2–11.2) months, and the median OS was 9.1 (range, 6.2–22.0) months. The median number of treatment cycles was three (range, 2–11). Grade 1/2 toxicities were observed in all patients. Grade 3/4 neutropenia was observed in four patients (80%), but there were no cases of febrile neutropenia. Conclusions: Despite the absence of the responders, the observation of SD in three patients suggests that AMR could have potential for treating MPM. Abstract : Despite the absence of the responders, the observation of SD in three patients suggests that AMR could have potential for treating MPM.